Advances in umbilical cord blood manipulation-from niche to bedside

Nature Reviews Clinical Oncology

Volumn 12, Issue 3, 2015, Pages 163-174

  Lund, Troy C ^a   Boitano, Anthony E ^b   Delaney, Colleen S ^c   Shpall, Elizabeth J ^d   Wagner, John E ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; COPPER; CYTOKINE; NICOTINAMIDE; NOTCH RECEPTOR; PROSTAGLANDIN; PURINE DERIVATIVE; STEM REGENIN 1; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

BONE MARROW; CELL FUNCTION; CELL HOMING; CELL MANIPULATION; CELL STIMULATION; CHELATION; CLINICAL TRIAL (TOPIC); COMPLEMENT SYSTEM; CORD BLOOD STEM CELL TRANSPLANTATION; CULTURE MEDIUM; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HLA MATCHING; HUMAN; MYELOID PROGENITOR CELL; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; STEM CELL EXPANSION; STEM CELL MOBILIZATION; STEM CELL NICHE; UMBILICAL CORD BLOOD; ALLOTRANSPLANTATION; CULTURE TECHNIQUE; CYTOLOGY; FETUS BLOOD; GRAFT SURVIVAL; METABOLISM; PROCEDURES; PROGNOSIS; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

CELL CULTURE TECHNIQUES; CORD BLOOD STEM CELL TRANSPLANTATION; FETAL BLOOD; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELLS; HUMANS; PROGNOSIS; TRANSLATIONAL MEDICAL RESEARCH; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84923789455     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.215     Document Type: Review

References (115)

1. Kita, K., Lee, J. O., Finnerty, C. C.&Herndon, D. N. Cord blood-derived hematopoietic stem/progenitor cells: current challenges in engraftment, infection, and ex vivo expansion. Stem Cells Int. 2011, 276193 (2011
2. Laughlin, M. J. et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N. Engl. J. Med. 351, 2265-2275 (2004
3. Ballen, K. K., Gluckman, E.&Broxmeyer, H. E. Umbilical cord blood transplantation: the first 25 years and beyond. Blood 122, 491-498 (2013
4. Broxmeyer, H. E. et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc. Natl Acad. Sci. USA 86, 3828-3832 (1989
5. Calvet, L. et al. Hematologic, immunologic reconstitution, and outcome of 342 autologous peripheral blood stem cell transplantations after cryopreservation in a -80 degrees C mechanical freezer and preserved less than 6 months. Transfusion 53, 570-578 (2013
6. Davies, S. M. et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 96, 4096-4102 (2000
7. Eapen, M. et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J. Clin. Oncol. 22, 4872-4880 (2004
8. Rubinstein, P. et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N. Engl. J. Med. 339, 1565-1577 (1998
9. Anasetti, C. et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N. Engl. J. Med. 367, 1487-1496 (2012
10. Avery, S et al. Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood 117, 3277-3285 (2011
11. Laughlin, M. J. et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N. Engl. J. Med. 344, 1815-1822 (2001
12. Dexter, T. M., Allen, T. D.&Lajtha, L. G. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J. Cell. Physiol. 91, 335-344 (1977
13. Broxmeyer, H. E. et al. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc. Natl Acad. Sci. USA 89, 4109-4113 (1992
14. Gabutti, V. et al. Expansion of cord blood progenitors and use for hemopoietic reconstitution. Stem Cells 11 (Suppl. 2), 105-112 (1993
15. Mayani, H., Dragowska, W.&Lansdorp, P. M. Cytokine-induced selective expansion and maturation of erythroid versus myeloid progenitors from purified cord blood precursor cells. Blood 81, 3252-3258 (1993
16. Migliaccio, A. R., Migliaccio, G., Durand, B., Mancini, G. C.&Adamson, J. W. The generation of colony-forming cells (CFC) and the expansion of hematopoiesis in cultures of human cord blood cells is dependent on the presence of stem cell factor (SCF). Cytotechnology 11, 107-113 (1993
17. Brugger, W., Scheding, S., Ziegler, B., Buhring, H. J.&Kanz, L. Ex vivo manipulation of hematopoietic stem and progenitor cells. Semin. Hematol. 37, 42-49 (2000
18. Shpall, E. J. et al. Transplantation of ex vivo expanded cord blood. Biol. Blood Marrow Transplant. 8, 368-376 (2002
19. Lee, S. J. et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110, 4576-4583 (2007
20. Zidar, B. L., Shadduck, R. K., Zeigler, Z.&Winkelstein, A. Observations on the anemia and neutropenia of human copper deficiency. Am. J. Hematol. 3, 177-185 (1977
21. Percival, S. S. Neutropenia caused by copper deficiency: possible mechanisms of action. Nutr. Rev. 53, 59-66 (1995
22. Peled, T. et al. Cellular copper content modulates differentiation and self-renewal in cultures of cord blood-derived CD34+ cells. Br. J. Haematol. 116, 655-661 (2002
23. Peled, T. et al. Linear polyamine copper chelator tetraethylenepentamine augments long-Term ex vivo expansion of cord blood-derived CD34+ cells and increases their engraftment potential in NOD/SCID mice. Exp. Hematol. 32, 547-555 (2004
24. de Lima, M. et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant. 41, 771-778 (2008
25. Barker, J. N., Weisdorf, D. J.&Wagner, J. E. Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. N. Engl. J. Med. 344, 1870-1871 (2001
26. Brunstein, C. G. et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 116, 4693-4699 (2010
27. Scaradavou, A. et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood 121, 752-758 (2013
28. Wagner, J. E. Should double cord blood transplants be the preferred choice when a sibling donor is unavailable? Best Pract. Res. Clin. Haematol. 22, 551-555 (2009
29. Verneris, M. R. et al. Relapse risk after umbilical cord blood transplantation: enhanced graft versus leukemia effect in recipients of 2 units. Blood 114, 4293-4299 (2009
30. Ramirez, P. et al. Factors predicting single-unit predominance after double umbilical cord blood transplantation. Bone Marrow Transplant. 47, 799-803 (2012
31. Cutler, C. et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 118, 6691-6697 (2011
32. Barker, J. N. et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105, 1343-1347 (2005
33. Haspel, R. L. et al. Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant. 41, 523-529 (2008
34. Somers, J. A. et al. Double umbilical cord blood transplantation: a study of early engraftment kinetics in leukocyte subsets using HLA-specific monoclonal antibodies. Biol. Blood Marrow Transplant. 19, 266-273 (2013
35. Andersson, E. R., Sandberg, R.&Lendahl, U. Notch signaling: simplicity in design, versatility in function. Development 138, 3593-3612 (2011
36. Sethi, N.&Kang, Y. Notch signalling in cancer progression and bone metastasis. Br. J. Cancer 105, 1805-1810 (2011
37. Milner, L. A., Kopan, R., Martin, D. I.&Bernstein, I. D. A human homologue of the Drosophila developmental gene, Notch, is expressed in CD34+ hematopoietic precursors. Blood 83, 2057-2062 (1994
38. Varnum-Finney, B. et al. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat. Med. 6, 1278-1281 (2000
39. Varnum-Finney, B. et al. Immobilization of Notch ligand, Delta 1, is required for induction of notch signaling. J. Cell Sci. 113, 4313-4318 (2000
40. Dallas, M H., Varnum-Finney, B., Martin, P. J.&Bernstein, I. D. Enhanced T cell reconstitution by hematopoietic progenitors expanded ex vivo using the Notch ligand Delta1. Blood 109, 3579-3587 (2007
41. Varnum-Finney, B., Brashem-Stein, C.&Bernstein, I. D. Combined effects of Notch signaling and cytokines induce a multiple log increase in precursors with lymphoid and myeloid reconstituting ability. Blood 101, 1784-1789 (2003
42. Delaney, C., Varnum-Finney, B., Aoyama, K., Brashem-Stein, C.&Bernstein, I. D. Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. Blood 106, 2693-2699 (2005).
43. Delaney, C. et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat. Med. 16, 232-236 (2010
44. Prockop, D. J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276, 71-74 (1997
45. Musina, R. A., Bekchanova, E. S.&Sukhikh, G. T. Comparison of mesenchymal stem cells obtained from different human tissues. Bull. Exp. Biol. Med. 139, 504-509 (2005
46. Crisan, M. et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3, 301-313 (2008
47. Corselli, M., Chen, C. W., Crisan, M., Lazzari, L.&Peault, B. Perivascular ancestors of adult multipotent stem cells. Arterioscler. Thromb. Vasc. Biol. 30, 1104-1109 (2010
48. Weber, J. M.&Calvi, L. M. Notch signaling and the bone marrow hematopoietic stem cell niche. Bone 46, 281-285 (2010
49. Caplan, A. I.&Dennis, J. E. Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 98, 1076-1084 (2006
50. Robinson, S. N. et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant. 37, 359-366 (2006
51. McNiece, I., Harrington, J., Turney, J., Kellner, J.&Shpall, E. J. Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. Cytotherapy 6, 311-317 (2004
52. de Lima, M. et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N. Engl. J. Med. 367, 2305-2315 (2012
53. Tang, B. L. Sirtl's systemic protective roles and its promise as a target in antiaging medicine. Transl. Res. 157, 276-284 (2011
54. Borradaile, N. M.&Pickering, J. G. NAD+, sirtuins, and cardiovascular disease. Curr. Pharm. Des. 15, 110-117 (2009
55. Narala, S. R. et al. SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. Mol. Biol. Cell 19, 1210-1219 (2008
56. Ou, X. et al. SIRT1 deficiency compromises mouse embryonic stem cell hematopoietic differentiation, and embryonic and adult hematopoiesis in the mouse. Blood 117, 440-450 (2011
57. Peled, T. et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp. Hematol. 40, 342-355.e1 (2012
58. Fruscione, F. et al. Regulation of human mesenchymal stem cell functions by an autocrine loop involving NAD+ release and P2Y11-mediated signaling. Stem Cells Dev. 20, 1183-1198 (2011
59. Li, Y., He, J., He, X., Li, Y.&Lindgren, U. Nampt expression increases during osteogenic differentiation of multi-And omnipotent progenitors. Biochem. Biophys. Res. Commun. 434, 117-123 (2013
60. Horwitz, M. E. et al. Umbilical cord blood expansion with nicotinamide provides long-Term multilineage engraftment. J. Clin. Invest. 124, 3121-3128 (2014
61. Boitano, A. E. et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329, 1345-1348 (2010
62. Dvorak, Z., Vrzal, R., Starha, P., Klanicova, A.&Travnicek, Z. Effects of dinuclear copper(II) complexes with 6 (benzylamino)purine derivatives on AhR and PXR dependent expression of cytochromes P450 CYP1A2 and CYP3A4 genes in primary cultures of human hepatocytes. Toxicol. In Vitro 24, 425-429 (2010
63. van Os, R. et al. Engraftment of syngeneic bone marrow is not more efficient after intrafemoral transplantation than after traditional intravenous administration. Exp. Hematol. 38, 1115-1123 (2010
64. Castello, S. et al. Intra-bone marrow injection of bone marrow and cord blood cells: an alternative way of transplantation associated with a higher seeding efficiency. Exp. Hematol. 32, 782-787 (2004
65. Brunstein, C. G. et al. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant. 43, 935-940 (2009
66. Frassoni, F. et al. The intra-bone marrow injection of cord blood cells extends the possibility of transplantation to the majority of patients with malignant hematopoietic diseases. Best Pract. Res. Clin. Haematol. 23, 237-244 (2010
67. Rocha, V. et al. Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. Transplantation 95, 1284-1291 (2013
68. Tashiro, K. et al. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 261, 600-603 (1993
69. Kim, C. H.&Broxmeyer, H. E. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell derived factor 1, steel factor, and the bone marrow environment. Blood 91, 100-110 (1998
70. Aiuti, A., Webb, I. J., Bleul, C., Springer, T.&Gutierrez-Ramos, J. C. The chemokine SDF 1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J. Exp. Med. 185, 111-120 (1997
71. Bleul, C. C., Fuhlbrigge, R. C., Casasnovas, J. M., Aiuti, A.&Springer, T. A. A highly efficacious lymphocyte chemoattractant, stromal cell derived factor 1 (SDF 1). J. Exp. Med. 184, 1101-1109 (1996
72. Peled, Aet al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283, 845-848 (1999
73. Christopherson, K. W. 2nd, Paganessi, L. A., Napier, S.&Porecha, N. K. CD26 inhibition on CD34+ or lineage- human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-Term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev. 16, 355-360 (2007
74. Broxmeyer, H. E. et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat. Med. 18, 1786-1796 (2012
75. Christopherson, K. W. 2nd, Hangoc, G.&Broxmeyer, H. E. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor 1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J. Immunol. 169, 7000-7008 (2002
76. Christopherson, K W. 2nd, Hangoc, G., Mantel, C. R.&Broxmeyer, H. E. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 305, 1000-1003 (2004
77. Farag, S. S. et al. In vivo DPP 4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev. 22, 1007-1015 (2013
78. Ratajczak, M. Z., Kim, C., Ratajczak, J.&Janowska-Wieczorek, A. Innate immunity as orchestrator of bone marrow homing for hematopoietic stem/progenitor cells. Adv. Exp. Med. Biol. 735, 219-232 (2013
79. Reca, R et al. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF 1. Blood 101, 3784-3793 (2003
80. Wysoczynski, M. et al. Defective engraftment of C3aR/-hematopoietic stem progenitor cells shows a novel role of the C3a C3aR axis in bone marrow homing. Leukemia 23, 1455-1461 (2009
81. Ratajczak, J. et al. Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood 103, 2071-2078 (2004
82. Brunstein, C. G. et al. Complement fragment 3a priming of umbilical cord blood progenitors: safety profile. Biol. Blood Marrow Transplant. 19, 1474-1479 (2013
83. North, T. E. et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 447, 1007-1011 (2007
84. Yagi, H. et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant. 19, 667-679 (2010
85. Hoggatt, J., Singh, P., Sampath, J.&Pelus, L. M. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood 113, 5444-5455 (2009
86. Aggarwal, S.&Pittenger, M. F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815-1822 (2005
87. English, K. et al. Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25High forkhead box P3+ regulatory T cells. Clin. Exp. Immunol. 156, 149-160 (2009
88. DeGowin, R. L.&Gibson, D. P. Prostaglandin-mediated enhancement of erythroid colonies by marrow stromal cells (MSC). Exp. Hematol. 9, 274-280 (1981
89. Cutler, C. et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 122, 3074-3081 (2013
90. Jetmore, A. et al. Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34+ cells transplanted into conditioned NOD/SCID recipients. Blood 99, 1585-1593 (2002
91. Orschell-Traycoff, C. M. et al. Homing and engraftment potential of Sca 1+lin- cells fractionated on the basis of adhesion molecule expression and position in cell cycle. Blood 96, 1380-1387 (2000
92. Geyer, M. B. et al. T cell depletion utilizing CD34+ stem cell selection and CD3+ addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients. Br. J. Haematol. 157, 205-219 (2012
93. Lang, P. et al. Transplantation of highly purified peripheral-blood CD34+ progenitor cells from related and unrelated donors in children with nonmalignant diseases. Bone Marrow Transplant. 33, 25-32 (2004
94. Peters, C. et al. Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment. Leukemia 13, 2070-2078 (1999
95. Arber, C. et al. Protection against lethal Aspergillus fumigatus infection in mice by allogeneic myeloid progenitors is not major histocompatibility complex restricted. J. Infect. Dis. 192, 1666-1671 (2005
96. Arber, C. et al. Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation. Blood 102, 421-428 (2003
97. BitMansour, A. et al. Myeloid progenitors protect against invasive aspergillosis and Pseudomonas aeruginosa infection following hematopoietic stem cell transplantation. Blood 100, 4660-4667 (2002
98. Broxmeyer, H. E.&Pelus, L. M. Inhibition of DPP4/CD26 and dmPGE2 treatment enhances engraftment of mouse bone marrow hematopoietic stem cells. Blood Cells Mol. Dis. 53, 34-38 (2014
99. Barker, J. N., Byam, C.&Scaradavou, A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood 117, 2332-2339 (2011
100. Wagner, J. E. et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N. Engl. J. Med. 371, 1685-1694 (2014).
101. Wahid, S. F. Indications and outcomes of reduced-Toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies. Int. J. Hematol. 97, 581-598 (2013
102. Bart, T. Cost effectiveness of cord blood versus bone marrow and peripheral blood stem cells. Clinicoecon. Outcomes Res. 2, 141-147 (2010
103. Majhail, N. S. et al. Costs of pediatric allogeneic hematopoietic-cell transplantation. Pediatr. Blood Cancer 54, 138-143 (2010
104. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00498316 (2014
105. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00469729?term=NCT00469729&rank=1 (2013
106. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01484470?term=NCT01484470&rank=1 (2014
107. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01221857?term=NCT01221857&rank=1 (2014
108. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01590628?term=NCT01590628&rank=1 (2014
109. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01816230?term=NCT01816230&rank=1 (2014
110. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01474681?term=NCT01474681&rank=1 (2014
111. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00963872?term=NCT00963872&rank=1 (2013
112. US National Library of Medicine ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00862719?term=NCT00862719&rank=1 (2014
113. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01720264?term=NCT01720264&rank=1 (2014
114. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00890500?term=NCT00890500&rank=1 (2013
115. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01527838?term=NCT01527838&rank=1 (2013